{"eventGroups":[{"description":"The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.\n\nbortezomib\n\nthalidomide","id":"EG000","otherNumAffected":25,"otherNumAtRisk":30,"seriousNumAffected":10,"seriousNumAtRisk":30,"title":"Bortezomib and Thalidomide"}],"frequencyThreshold":"5","otherEvents":[{"organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":30,"numEvents":75}],"term":"peripheral neuropathy"},{"organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":30,"numEvents":7}],"term":"hypotension"},{"organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":30,"numEvents":48}],"term":"fatigue"},{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":30,"numEvents":40}],"term":"constipation"},{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":30,"numEvents":29}],"term":"diarrhoea"}],"seriousEvents":[{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30,"numEvents":2}],"term":"dehydration"},{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30,"numEvents":2}],"term":"nausea & vomiting"},{"organSystem":"Renal and urinary disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1}],"term":"renal failure"},{"organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1}],"term":"neutropenic fever"},{"organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30,"numEvents":3}],"term":"pneumonia"},{"organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1}],"term":"hyperkalemia"}]}